CN116710135A - 用于治疗眼部疾病的方法和试剂 - Google Patents

用于治疗眼部疾病的方法和试剂 Download PDF

Info

Publication number
CN116710135A
CN116710135A CN202180082106.9A CN202180082106A CN116710135A CN 116710135 A CN116710135 A CN 116710135A CN 202180082106 A CN202180082106 A CN 202180082106A CN 116710135 A CN116710135 A CN 116710135A
Authority
CN
China
Prior art keywords
antibody
sequence
cdr3
seq
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180082106.9A
Other languages
English (en)
Chinese (zh)
Inventor
B·齐格拉
G·雷德利赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
6 Line Biotechnology Cos
Original Assignee
6 Line Biotechnology Cos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020903624A external-priority patent/AU2020903624A0/en
Application filed by 6 Line Biotechnology Cos filed Critical 6 Line Biotechnology Cos
Publication of CN116710135A publication Critical patent/CN116710135A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202180082106.9A 2020-10-07 2021-10-07 用于治疗眼部疾病的方法和试剂 Pending CN116710135A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020903624 2020-10-07
AU2020903624A AU2020903624A0 (en) 2020-10-07 Methods and agents for the treatment of ocular disease
PCT/AU2021/051173 WO2022073072A1 (en) 2020-10-07 2021-10-07 Methods and agents for the treatment of ocular disease

Publications (1)

Publication Number Publication Date
CN116710135A true CN116710135A (zh) 2023-09-05

Family

ID=81127099

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180082106.9A Pending CN116710135A (zh) 2020-10-07 2021-10-07 用于治疗眼部疾病的方法和试剂

Country Status (8)

Country Link
US (3) US11618782B2 (https=)
EP (1) EP4225796A4 (https=)
JP (1) JP2023545579A (https=)
KR (1) KR20230086713A (https=)
CN (1) CN116710135A (https=)
AU (1) AU2021356298A1 (https=)
IL (1) IL301762A (https=)
WO (1) WO2022073072A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
AU2021356298A1 (en) 2020-10-07 2023-05-04 Line 6 Biotechnology, Inc Methods and agents for the treatment of ocular disease
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820858A (en) 1993-05-28 1998-10-13 The Scripps Research Institute Methods and compositions for inhibiting CD14 mediated cell activation
AU2001290315A1 (en) 2000-11-22 2002-06-03 Mochida Pharmaceutical Co., Ltd. Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding
WO2006063292A1 (en) * 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
US20060257411A1 (en) * 2005-05-06 2006-11-16 Bruce Beutler Compositions and methods for modulating cells via CD14 and toll-like receptor 4 signaling pathway
WO2009002790A2 (en) * 2007-06-26 2008-12-31 Bausch & Lomb Incorporated Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing dry eye
WO2009089401A2 (en) * 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Compositions comprising toll-like receptor or coreceptor antagonists and methods for treating or controlling ocular allergy using same
PT3065761T (pt) * 2013-11-05 2020-02-21 Allergan Inc Método de tratamento de condições oculares com um darpin anti-vegf
AU2014370404A1 (en) * 2013-12-24 2016-07-07 Novelmed Therapeutics, Inc. Compositions and methods of treating ocular diseases
EP2898896A1 (en) * 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
US20160038589A1 (en) * 2014-08-11 2016-02-11 Ophthotech Corporation Methods for treating or preventing ophthalmological conditions
US10407510B2 (en) * 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
IL309046B2 (en) * 2017-04-21 2025-03-01 Implicit Bioscience Ltd CD14 antagonist antibodies for the treatment of neurodegenerative diseases
KR20190059164A (ko) * 2017-11-22 2019-05-30 건국대학교 글로컬산학협력단 가용성 cd14의 당뇨황반부종 진단 및 치료 용도
AU2021356298A1 (en) 2020-10-07 2023-05-04 Line 6 Biotechnology, Inc Methods and agents for the treatment of ocular disease

Also Published As

Publication number Publication date
AU2021356298A1 (en) 2023-05-04
JP2023545579A (ja) 2023-10-30
US20220220194A1 (en) 2022-07-14
AU2021356298A9 (en) 2024-04-18
US20240002489A1 (en) 2024-01-04
IL301762A (en) 2023-05-01
US12258390B2 (en) 2025-03-25
KR20230086713A (ko) 2023-06-15
WO2022073072A1 (en) 2022-04-14
US11618782B2 (en) 2023-04-04
EP4225796A4 (en) 2024-11-13
US20250230228A1 (en) 2025-07-17
EP4225796A1 (en) 2023-08-16

Similar Documents

Publication Publication Date Title
TWI419704B (zh) 預防及治療與補體相關之眼部病症
US12258390B2 (en) Methods and agents for the treatment of ocular disease
JP7760626B2 (ja) 治療に使用するための抗ソルチリン抗体
CA3078974A1 (en) Vegfr-antibody light chain fusion protein
CN113544151B (zh) 抗il-27抗体及其用途
JP2023520516A (ja) 抗ｔｒｅｍ２抗体の使用方法
JP2018530574A (ja) 患者の加齢黄斑変性を治療する方法
JP2023551734A (ja) 眼の疾患を治療するための組成物及び方法
KR20230146053A (ko) 보체 c3 항원 결합 단백질
US20240101681A1 (en) Methods of use of anti-sortilin antibodies
US20240132597A1 (en) Methods of use of anti-sortilin antibodies
KR20250021399A (ko) 안지오포이에틴-관련 단백질 7-특이적 항체 및 그의 용도
TW202426494A (zh) 預測對ｉｌ－６拮抗劑的反應
HK40121389A (zh) 预测对il-6拮抗剂的反应
WO2019074912A1 (en) ANTI-IL-33 THERAPY FOR ATOPIC DERMATITIS
NZ735964B2 (en) Antibodies Specific For TGF-Beta
NZ717933A (en) Antibodies specific for tgf-beta

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination